https://scholars.lib.ntu.edu.tw/handle/123456789/551288
標題: | Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: A retrospective analysis covering a 34-year period | 作者: | Chen H.H.W. Fong L. Su I.-J. Ting L.-L. RUEY-LONG HONG Leung H.W.C. Lui L.T. |
關鍵字: | Lethal midline granuloma; Radiotherapy; T-cell lymphoma | 公開日期: | 1996 | 出版社: | Elsevier Ireland Ltd | 卷: | 38 | 期: | 1 | 起(迄)頁: | 1-6 | 來源出版物: | Radiotherapy and Oncology | 摘要: | Lethal midline granuloma (LMG) is characterized by progressive ulceration and destruction of the midfacial tissue. It occurs more frequently in Oriental than in Western populations. Because of the progress in clinical pathology and immunohistochemistry, most cases have been proven to be malignant lymphomas, especially of T-cell lineage. We describe 92 cases of lethal midline granuloma or centrofacial malignant lymphoma in the period 1959-1993. All received complete courses of radiotherapy. Twenty of them also received combination chemotherapy. Thirty-six cases had specimens available for immunohistochemical study; 25 (69%) of these had a T-cell phenotype, and 6 (17%) were of B-cell lineage. The dose to the nasal region was in the range of 3000-7500 cGy in 11-58 days, and to the neck 3000-6400 cGy in 11-48 days. The overall survival rate for the LMGs was 59.5% at 5 years and 56.2% at 10 years (Kaplan-Meier). Combined chemotherapy seemed not to improve the overall survival in this study (p = 0.63), but the patient number was too small to make a firm conclusion. Based on the results of this study, we recommend a dose of 4500-5000 cGy to the midfacial region, since a higher dosage did not improve the treatment results (p = 0.88). Irradiation has a definite role in good locoregional control of this disease. The recent clarification of the disease nature and the recognition of the background clinicopathological features should provide valuable information for future patient management and prospective studies. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030061372&doi=10.1016%2f0167-8140%2895%2901668-6&partnerID=40&md5=3d157695e8a4d05ca88d50c94847ce78 https://scholars.lib.ntu.edu.tw/handle/123456789/551288 |
ISSN: | 0167-8140 | DOI: | 10.1016/0167-8140(95)01668-6 | SDG/關鍵字: | chlormethine; cyclophosphamide; doxorubicin; epirubicin; prednisone; procarbazine; vincristine; adolescent; adult; aged; article; cancer radiotherapy; child; female; human; major clinical study; male; midline granuloma; priority journal; T cell lymphoma |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。